Actemra Infusion 400 Mg/20 ML 1 Vialx20 ML

Actemra 400 mg/20 mL Infusion contains Tocilizumab, a monoclonal antibody that treats moderate to severe rheumatoid arthritis (RA), Giant Cell Arteritis (GCA), Systemic Juvenile Idiopathic Arthritis (SJIA), and Cytokine Release Syndrome (CRS). It inhibits the interleukin-6 (IL-6) receptor, reduces inflammation, and slows down the progression of autoimmune diseases.

Healthcare professionals should administer this product as a single-use 20 mL vial containing 400 mg of Tocilizumab, designed for intravenous infusion. Actemra provides a widely trusted treatment option for patients who have not responded adequately to traditional Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

Key Features:
Strength: 400 mg/20 mL per vial

Formulation: Concentrated solution for IV infusion

Active Ingredient: Tocilizumab

Manufacturer: [Insert Manufacturer Name]

Indications: RA, GCA, SJIA, CRS

For more autoimmune treatments, visit our Medicine Collection.

Usage & Administration:
The patient’s medical condition and body weight determine the dosage and infusion schedule. Always follow the prescribed dosing regimen provided by your healthcare provider. Do not self-administer.

Storage Instructions:
Store the vial in a refrigerator at 2°C to 8°C. Do not freeze. Keep away from direct light and out of reach of children.

Important Information:
A prescription is required.

Consult your doctor regarding potential side effects, including infections, liver enzyme elevations, and gastrointestinal perforations.